Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19773151 | 1.00 | EPHX2 (0.54) | EPHX2ALDH1A1KDM4EPHGDHMGLL | |
| SCHEMBL14035661 | 0.98 | ALDH1A1 (0.55) | EPHX2ALDH1A1KDM4EPHGDHMGLL | |
| SCHEMBL15932473 | 0.90 | ALDH1A1 (0.46) | EPHX2ALDH1A1KDM4EKMT2ATSHR | |
| SCHEMBL8229259 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KDM4EPHGDHMGLLPOLB | |
| SCHEMBL12452076 | 0.85 | MEN1 (0.56) | EPHX2ALDH1A1KDM4EKMT2A | |
| SCHEMBL13612604 | 0.84 | L3MBTL3 (0.51) | EPHX2ALDH1A1KDM4E | |
| SCHEMBL12313355 | 0.83 | MEN1 (0.54) | EPHX2ALDH1A1KDM4EKMT2A | |
| SCHEMBL24402289 | 0.82 | NPC1 (0.46) | EPHX2ALDH1A1KDM4EPOLBKMT2A | |
| SCHEMBL12801522 | 0.82 | NPC1 (0.46) | EPHX2ALDH1A1KDM4EPOLBKMT2A | |
| SCHEMBL18909113 | 0.82 | EPHX2 (0.44) | EPHX2ALDH1A1KDM4EKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | EPHX2 3198/4885ALDH1A1 662/4885KDM4E 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.